Published in Cancer Res on July 15, 2007
Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res (2010) 1.26
Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. Cancer Res (2010) 1.20
The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate RhoB-mediated cell death after DNA damage. PLoS One (2011) 1.02
Superparamagnetic iron oxide nanoparticles: amplifying ROS stress to improve anticancer drug efficacy. Theranostics (2013) 0.91
Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone. Cancer Metab (2015) 0.88
Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol (2015) 0.88
Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer. J Gastroenterol (2011) 0.87
Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers. Antioxid Redox Signal (2014) 0.86
Enhanced genotoxicity of silver nanoparticles in DNA repair deficient Mammalian cells. Front Genet (2012) 0.84
Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells. PLoS One (2014) 0.84
Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways. Clin Pharmacol (2015) 0.80
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone. Sci Rep (2015) 0.80
β-Lapachone ameliorization of experimental autoimmune encephalomyelitis. J Neuroimmunol (2012) 0.77
eIF2 kinases mediate β-lapachone toxicity in yeast and human cancer cells. Cell Cycle (2015) 0.77
Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights. Eur J Med Chem (2016) 0.77
Lysosome-oriented, dual-stage pH-responsive polymeric micelles for β-Lapachone delivery. J Mater Chem B Mater Biol Med (2016) 0.75
Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett (2006) 3.94
Retracted Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol (2003) 2.83
Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem (2011) 2.46
Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart (2012) 2.41
Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A (2010) 2.16
Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem (2003) 2.01
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci U S A (2007) 1.92
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res (2009) 1.79
Mu-calpain activation in beta-lapachone-mediated apoptosis. Cancer Biol Ther (2003) 1.76
DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem (2004) 1.65
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res (2009) 1.64
cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed Engl (2004) 1.63
Role of 4-1BB in allograft rejection mediated by CD8+ T cells. Am J Transplant (2003) 1.61
Mutants of Arabidopsis lacking a chloroplastic isoamylase accumulate phytoglycogen and an abnormal form of amylopectin. Plant Physiol (2005) 1.54
Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene (2003) 1.52
TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest (2009) 1.50
Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. J Biol Chem (2006) 1.43
Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem (2005) 1.36
Changes in susceptibility of Plasmodium falciparum to artesunate in vitro in Yunnan Province, China. Trans R Soc Trop Med Hyg (2003) 1.33
In vivo off-resonance saturation magnetic resonance imaging of alphavbeta3-targeted superparamagnetic nanoparticles. Cancer Res (2009) 1.32
Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol (2009) 1.26
Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res (2010) 1.26
Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. J Biol Chem (2008) 1.25
An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Cancer Res (2012) 1.24
The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res (2009) 1.22
Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. Cancer Res (2010) 1.20
Advances and challenges in basic and translational research on clusterin. Cancer Res (2009) 1.20
Up-regulation of C-terminal tensin-like molecule promotes the tumorigenicity of colon cancer through beta-catenin. Cancer Res (2009) 1.18
Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery. ACS Nano (2011) 1.17
Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin Cancer Res (2009) 1.16
Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release (2007) 1.15
Involvement of the brain (pro)renin receptor in cardiovascular homeostasis. Circ Res (2010) 1.14
The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci (2004) 1.14
Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels. Clin Cancer Res (2005) 1.13
IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects. Mutat Res (2004) 1.13
Cytosolic phospholipase A2 (cPLA2) regulation of human monocyte NADPH oxidase activity. cPLA2 affects translocation but not phosphorylation of p67(phox) and p47(phox). J Biol Chem (2002) 1.11
Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes. Pharm Res (2003) 1.10
Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. Diagn Pathol (2013) 1.09
Further evidence for the mandatory nature of polysaccharide debranching for the aggregation of semicrystalline starch and for overlapping functions of debranching enzymes in Arabidopsis leaves. Plant Physiol (2008) 1.09
Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. Mol Cancer Ther (2013) 1.08
RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN. Cancer Res (2009) 1.08
DNA mismatch repair-dependent activation of c-Abl/p73alpha/GADD45alpha-mediated apoptosis. J Biol Chem (2008) 1.07
Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. Cancer Epidemiol Biomarkers Prev (2010) 1.07
DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. Br J Pharmacol (2009) 1.07
Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. Clin Cancer Res (2011) 1.06
Stress-induced premature senescence (SIPS)--influence of SIPS on radiotherapy. J Radiat Res (2008) 1.06
Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. Clin Cancer Res (2009) 1.04
Impact of bile acids on the growth of human cholangiocarcinoma via FXR. J Hematol Oncol (2011) 1.03
New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. J Mol Histol (2006) 1.02
A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene (2003) 1.02
Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. Cancer Biol Ther (2005) 1.01
Long-term survival of intestinal allografts induced by costimulation blockade, busulfan and donor bone marrow infusion. Am J Transplant (2003) 1.00
Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen (2004) 1.00
Frequent mutation related with overexpression of DNA polymerase beta in primary tumors and precancerous lesions of human stomach. Cancer Lett (2005) 0.98
Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation. Int J Radiat Oncol Biol Phys (2005) 0.97
Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses. J Biol Chem (2008) 0.97
Quantitative studies on structure-DPPH• scavenging activity relationships of food phenolic acids. Molecules (2012) 0.95
Modulating beta-lapachone release from polymer millirods through cyclodextrin complexation. J Pharm Sci (2006) 0.95
Opposing effect of EGFRWT on EGFRvIII-mediated NF-κB activation with RIP1 as a cell death switch. Cell Rep (2013) 0.94
Improved protein arrays for quantitative systems analysis of the dynamics of signaling pathway interactions. Proteome Sci (2011) 0.94
Loss of p15/Ink4b accompanies tumorigenesis triggered by complex DNA double-strand breaks. Carcinogenesis (2010) 0.94
Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Neoplasia (2007) 0.94
Photoactivation switch from type II to type I reactions by electron-rich micelles for improved photodynamic therapy of cancer cells under hypoxia. J Control Release (2011) 0.93
Repression of IR-inducible clusterin expression by the p53 tumor suppressor protein. Cancer Biol Ther (2003) 0.93
Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancers. Neoplasia (2007) 0.92
The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer Res (2013) 0.92
Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. Int J Nanomedicine (2006) 0.91
Superparamagnetic iron oxide nanoparticles: amplifying ROS stress to improve anticancer drug efficacy. Theranostics (2013) 0.91
The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK/T-cell lymphoma, nasal type. J Exp Clin Cancer Res (2014) 0.90
Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biol Chem (2008) 0.90
Direct synthesis of highly substituted 2-cyclohexenones and sterically hindered benzophenones based on a [5C + 1C] annulation. J Org Chem (2009) 0.90
Rapid authentication of olive oil adulteration by Raman spectrometry. J Agric Food Chem (2009) 0.90